XML 24 R10.htm IDEA: XBRL DOCUMENT
v3.19.3

Revenue | 9 Months Ended
--- | ---
Sep. 30, 2019
Revenue [Abstract] |
Revenue from Contract with Customer [Text Block] | Revenue The following table presents the approximate percentage of our net sales by market group:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2019 |  | 2018 |  | 2019 |  | 2018
Biologics | 26 | % |  | 21 | % |  | 25 | % |  | 21 | %
Generics | 20 | % |  | 21 | % |  | 20 | % |  | 21 | %
Pharma | 30 | % |  | 34 | % |  | 31 | % |  | 35 | %
Contract-Manufactured Products | 24 | % |  | 24 | % |  | 24 | % |  | 23 | %
| 100 | % |  | 100 | % |  | 100 | % |  | 100 | %
The following table presents the approximate percentage of our net sales by product category:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2019 |  | 2018 |  | 2019 |  | 2018
High-Value Components | 42 | % |  | 41 | % |  | 43 | % |  | 42 | %
Standard Packaging | 28 | % |  | 31 | % |  | 29 | % |  | 32 | %
Delivery Devices | 6 | % |  | 4 | % |  | 4 | % |  | 3 | %
Contract-Manufactured Products | 24 | % |  | 24 | % |  | 24 | % |  | 23 | %
| 100 | % |  | 100 | % |  | 100 | % |  | 100 | %
The following table presents the approximate percentage of our net sales by geographic location:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2019 |  | 2018 |  | 2019 |  | 2018
Americas | 48 | % |  | 51 | % |  | 48 | % |  | 48 | %
Europe, Middle East, Africa | 44 | % |  | 41 | % |  | 44 | % |  | 44 | %
Asia Pacific | 8 | % |  | 8 | % |  | 8 | % |  | 8 | %
| 100 | % |  | 100 | % |  | 100 | % |  | 100 | %
Contract Assets and Liabilities The following table summarizes our contract assets and liabilities, excluding contract assets included in accounts receivable, net:
| ($ in millions)
Contract assets, December 31, 2018 | $ | 9.1 |
Contract assets, September 30, 2019 | 9.4 |
Change in contract assets - increase (decrease) | $ | 0.3 |
Deferred income, December 31, 2018 | $ | (33.4 | )
Deferred income, September 30, 2019 | (30.9 | )
Change in deferred income - decrease (increase) | $ | 2.5 |
The decrease in deferred income during the nine months ended September 30, 2019 was primarily due to the recognition of revenue of $79.3 million, including $18.0 million of revenue that was included in deferred income at the beginning of the year, and $2.7 million in other adjustments, partially offset by additional cash payments of $79.5 million received in advance of satisfying future performance obligations. The majority of the performance obligations within our contracts are satisfied within one year or less. Performance obligations satisfied beyond one year include those relating to a nonrefundable customer payment of $20.0 million received in June 2013 in return for the exclusive use of the SmartDose® technology platform within a specific therapeutic area. As of September 30, 2019, there was $5.9 million of unearned income related to this payment, of which $0.9 million was included in other current liabilities and $5.0 million was included in other long-term liabilities. The unearned income is being recognized as income on a straight-line basis over the remaining term of the agreement. The agreement does not include a future minimum purchase commitment from the customer. Supply Chain Financing We have entered into supply chain financing agreements with certain banks, pursuant to which we offer for sale certain accounts receivable to such banks from time to time, subject to the terms of the applicable agreements. These transactions result in a reduction in accounts receivable, as the agreements transfer effective control over, and credit risk related to, the receivables to the banks. These agreements do not allow for recourse in the event of uncollectibility, and we do not retain any interest in the underlying accounts receivable once sold. As of September 30, 2019, we derecognized $7.9 million of accounts receivable under these agreements. Discount fees related to the sale of such accounts receivable on our condensed consolidated income statements for the nine months ended September 30, 2019 were not material. Voluntary Recall On January 24, 2019, we issued a voluntary recall of our Vial2Bag® product line due to reports of potential unpredictable or variable dosing under certain conditions. Our fourth quarter 2018 results included an $11.3 million provision for product returns, recorded as a reduction of sales, partially offset by a reduction in cost of goods sold reflecting our inventory balance for these devices at December 31, 2018. During the three and nine months ended September 30, 2019, we recorded a net adjustment of $0.9 million and a net provision of $4.9 million, respectively, for potential inventory returns from our customers and related in-house inventory, partially offset by a reduction in our provision for product returns. We continue to work to get the products back on the market.

X
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -URI http://asc.fasb.org/topic&trid=49130388 + Details
Name: | us-gaap_RevenueFromContractWithCustomerTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue [Abstract] + References No definition available. + Details
Name: | wst_RevenueAbstract
Namespace Prefix: | wst_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration